

Meiji Seika Pharma Co., Ltd.

July 9, 2024

**Results from Phase III Study of Belumosudil, Selective ROCK2 Inhibitor,
in Patients with Steroid-Dependent/Resistant cGVHD in Japan
Published in American Journal of Hematology**

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) announced that results from the Phase III clinical trial of belumosudil (JAN: belumosudil mesylate, Product name in Japan: *REZUROCK® Tablets*), a selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with steroid-dependent/resistant chronic graft-versus-host disease (cGVHD) conducted in Japan ([jRCT2011210041](#)) were published in the [American Journal of Hematology](#) on June 27, 2024.

The authors reported that, based on the 24-week results of a multicenter, open-label, single-arm phase III clinical trial conducted in 21 Japanese patients with steroid-dependent/resistant cGVHD, belumosudil was effective as second or subsequent line of therapy for the disease, with no new safety concerns ⁽¹⁾. For more information, please access to the article.

The results from the Phase III study were also presented at the 46th JSTCT Annual Meeting ([JSTC2024](#)) of the Japanese Society for Transplantation and Cellular Therapy held in Tokyo on March 22, 2024. ([Press release on March 22](#))

Belumosudil (*REZUROCK®*) is commercially available to prescribed patients in several countries worldwide, including US from 2021, Canada and Great Britain from 2023, Gulf, China and Israel from 2024. In Japan and 12 Asian countries, Romeck Pharma LLC, the joint venture between Meiji and Kadmon Corporation LLC (Headquarters: New York City, USA), a Sanofi company, has the exclusive right to develop and commercialize *REZUROCK®*.

Meiji Seika Pharma will address unmet medical needs in the field of hematology by distributing *REZUROCK®* for the treatment of cGVHD in Japan.

Reference:

- (1) Inamoto Y, et al. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD. *Am J Hematol.* 2024 Jun 27. doi: 10.1002/ajh.27424.